Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

ADC payload

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (19) ADC Linker (1) Drug-Linker Conjugates for ADC (18) Antibody-Drug Conjugates (ADCs) (7) Apoptosis (1) Bacterial (2) Bcl-2 Family (1) CD22 (1) DNA Alkylator/Crosslinker (4) Drug Metabolite (1) EGFR (3) FGFR (1) Glucocorticoid Receptor (1) Microtubule/Tubulin (5) NAMPT (3) PROTAC Linkers (1) Topoisomerase (2)
By Research Areas:	Cancer (47) Inflammation/Immunology (1) Metabolic Disease (1)
Click Chemistry:	ADC Synthesis (1) DBCO (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Click Chemistry

Targets Recommended: ADC Cytotoxin ADC Antibody ADC Linker Drug-Linker Conjugates for ADC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148128

TAM470	Microtubule/Tubulin ADC Cytotoxin	Cancer
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .

HY-15581

MMAD Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10	Microtubule/Tubulin ADC Cytotoxin	Cancer
MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).

HY-132162

7-MAD-MDCPT	ADC Cytotoxin	Cancer
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	ADC Cytotoxin	Cancer
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effcts. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-164787

N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine	ADC Cytotoxin Microtubule/Tubulin	Cancer
N-MeVal-Val-Dil-Dap-2-(pyridin-3-yl)ethanamine (Compound 14) is a tubulin polymerization inhibitor that can be used as an ADC payload .

HY-156249

NMS-P528	ADC Cytotoxin	Cancer
NMS-P528 is a Duocarmycin derivative that can be used as an **ADC payload**. NMS-P528 can be used to synthesize NMS-P945 .

HY-132158

MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin	Drug-Linker Conjugates for ADC	Cancer
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC) .

HY-107502

Cryptophycin analog 1	Others	Cancer
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 .

HY-164705

Mal-Toxophore	Drug-Linker Conjugates for ADC	Cancer
Mal-Toxophore is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164759) .

HY-164707

MC7	Drug-Linker Conjugates for ADC	Cancer
MC7 is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-402237) .

HY-169324

APL-1092 Mal-Exo-EEVC-Exatecan	Drug-Linker Conjugates for ADC	Cancer
APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker conjugate for ADC, which contains Exatecan (HY-13631) (ADC payload) and a linker .

HY-156756

7-Hydroxymethyl-10,11-MDCPT	ADC Cytotoxin	Others
7-Hydroxymethyl-10,11-MDCPT is a payload that can be used for *ADC* synthesis .

HY-126663

N-Me-L-Ala-maytansinol	ADC Cytotoxin	Cancer
N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used for making antibody-drug conjugate *(ADC)* .

HY-101127

SGD-1882 PBD dimer	ADC Cytotoxin	Cancer
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.

HY-164706

m-PEG6-Lys-Mal-Toxophore-quinoline	Drug-Linker Conjugates for ADC	Cancer
m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164760) .

HY-137774

Clezutoclax	ADC Cytotoxin Bcl-2 Family Drug-Linker Conjugates for ADC	Cancer
Clezutoclax is a potent payload and also a Bcl-XL inhibitor. Clezutoclax can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-144880

SC209	ADC Cytotoxin EGFR Drug Metabolite	Cancer
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is the payload of STRO-002 .

HY-157078

Eg5-IN-2	ADC Cytotoxin	Cancer
Eg5-IN-2 (Compound Scaffold B (4)) is an Eg5 inhibitor (IC₅₀: < 0.5 nM). Eg5-IN-2 can be used as an ADC payload for synthesis of ADCs .

HY-147408

Rezetecán SHR9265	Topoisomerase ADC Cytotoxin	Cancer
Rezetecán (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecán can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload .

HY-136297

DGN549-C	Drug-Linker Conjugates for ADC	Cancer
DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel DNA-alkylating cytotoxic payload and can be used in the synthesis of antibody-agent conjugates (ADCs) .

HY-101141

sulfo-SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.

HY-154915

MC-EVCit-PAB-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-164730

Epratuzumab Tesirine ADCT-602; hLL2-Cys-PBD	Antibody-Drug Conjugates (ADCs)	Cancer
Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG3249 .

HY-128952

Tesirine 3 Publications Verification SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-12460

SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.

HY-101161

SG3199 2 Publications Verification	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) .

HY-153909

SMP-33693	Drug-Linker Conjugates for ADC	Cancer
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-153908

SMP-93566	Drug-Linker Conjugates for ADC	Cancer
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

HY-145078

PNU-EDA-Gly5	Drug-Linker Conjugates for ADC	Cancer
PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5 .

HY-163672

Glucocorticoid receptor modulator 3	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology
Glucocorticoid receptor modulator 3 (Payload 6) is a thioester-containing glucocorticoid receptor modulator (IC₅₀=0.6 nM). Glucocorticoid receptor modulator 3 is designed to inactivate unconjugated payloads rapidly through liver metabolism, thereby minimizing systemic exposure. Glucocorticoid receptor modulator 3 can be utilized in the development of antibody-drug conjugates (ADCs) targeting autoimmune diseases .

HY-135901

Py-MPB-amino-C3-PBD	ADC Cytotoxin Bacterial	Cancer
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-112616

NAMPT inhibitor-linker 2	NAMPT Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 2 is a agent-linker conjugates for *ADC, composed of an NAMPT* inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC₅₀s of <7 pM and 40 pM, respectively.

HY-112615

NAMPT inhibitor-linker 1	Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 1 is a agent-linker conjugates for *ADC, composed of an NAMPT* inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC₅₀s of <3 pM and 9 pM, respectively.

HY-130161

m-PEG4-Br	ADC Linker PROTAC Linkers	Cancer
m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907). m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency . m-PEG4-Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.

HY-129589

Thailanstatin A 1 Publications Verification	ADC Cytotoxin	Cancer
Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC₅₀=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC₅₀s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC .

HY-147193

Nampt-IN-10 TFA	NAMPT	Cancer
Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 TFA shows cellular potency to A2780 and CORL23 cells lines with IC₅₀s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs .

HY-147193A

Nampt-IN-10 trihydrochloride	NAMPT	Cancer
Nampt-IN-10 trihydrochloride (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 trihydrochloride shows cellular potency to A2780 and CORL23 cell lines with IC₅₀ values of 5 and 19 nM, respectively. Nampt-IN-10 trihydrochloride can be used as a novel non-antimitotic payload for antibody-drug conjugate (ADC) .

HY-147363

DIBAC-GGFG-NH2CH2-Dxd	Drug-Linker Conjugates for ADC	Others
DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

HY-135900

Aniline-MPB-amino-C3-PBD	ADC Cytotoxin Bacterial	Cancer
Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Aniline-MPB-amino-C3-PBD is a sequence-selective DNA minor-groove binding agent. Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-151207

Anticancer agent 81	Apoptosis ADC Cytotoxin	Cancer
Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab .

HY-24144

Tesirine intermediate-2	DNA Alkylator/Crosslinker	Cancer
Tesirine intermediate-2 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.

HY-47820

Tesirine intermediate-1	DNA Alkylator/Crosslinker	Cancer
Tesirine intermediate-1 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.

HY-148424

PBD dimer-2	ADC Cytotoxin	Cancer
PBD dimer-2 (compound 2c) is a C8-linked pyrrolobenzodiazepine dimer. PBD dimer-2 can span an extra base pair and cross-link the 5′-Pu-GA(T/A)TC-Py sequence. PBD dimer-2 can be used as a payload for antibody–agent conjugates (ADCs), and it can be used for the research of cancer .

HY-164763

SHR-A1201	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .

HY-164762

Trastuzumab rezetecan SHR-A1811	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-P99829

Cofetuzumab pelidotin PF-06647020; ABBV-647; h6M24-vc0101	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting *ADC* comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC₅₀ of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .

HY-164761

Anti-CD22-NMS249	Antibody-Drug Conjugates (ADCs) CD22	Cancer
Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC). Anti-CD22-NMS249 is composed of a humanized anti-CD22 antibody Pinatuzumab (HY-P99230), a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor payload PNU-159682 (HY-16700). Anti-CD22-NMS249 can be used for research in non-Hodgkin lymphoma (NHL) .

HY-153360

MC-GGFG-AM-(10Me-11F-Camptothecin)	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

106 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 106 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Target	Research Area